• Product NameKX2-391
• Brief DescriptionInhibitors
• Purification99.43%
• Biological ActivityKX2-391, the first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines. Phase 2.
• Target NameSrc inhibitor
• CAS No. 897016-82-9
• Calculated MW 431.53
• Formulation C26H29N3O3
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Cancer
  SMILES:O=C(CC1=CC=C(C=N1)C1=CC=C(OCCN2CCOCC2)C=C1)NCC1=CC=CC=C1 |c:5,7,24,31,33,t:3,10,12,29|
  Pathways:Angiogenesis
  Receptor:Src (Hep 3B); Src (Hep G2); Src (HuH7); Src (PLC/PRF/5)
  Boling pt:
  Melting pt:
  Solubility:DMSO:86 mg/mL (199.29 mM)Ethanol:<1 mg/mL (<1 mM)Water:<1 mg/mL (<1 mM)
  Appearance:
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Lau GM, et al, Dig Dis Sci, 2009, 54(7), 1465-1474.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting